Table 2.

Adjusted mean* at baselinea and percent change in biomarkers with 95% CI for stretching control and resistance training and groups

Control (n = 106)Resistance (n = 109)
BiomarkerMean (95% CI)% Change over 1 yearMean (95% CI)% Change over 1 yearP
CRPa1.2 (0.7–2.0)57.1 (10.5–123.2)1.3 (0.5–3.5)−4.0 (−58.3–120.9)0.045
IL1β0.3 (0.2–0.4)−5.9 (−17.8–7.8)0.3 (0.1–0.5)1.8 (−26.5–40.9)0.420
IL61.9 (1.3–2.7)−4.5 (−27.0–24.8)2.0 (0.9–4.3)−8.2 (−51.7–74.3)0.836
IL85.9 (5.0–6.9)−9.5 (−18.1–0.0)5.9 (4.2–8.1)−2.8 (−23.5–23.4)0.314
TNFα7.0 (5.8–8.4)−6.4 (−16.8–5.2)7.3 (5.0–10.5)−4.5 (−27.9–26.4)0.808
Adiponectin25.9 (22.0–30.5)0.8 (−10.0–12.8)27.8 (20.1–38.5)−7.8 (−29.5–20.7)0.266
Leptin11.6 (8.7–15.3)8.5 (−5.4–24.4)9.9 (5.7–17.2)3.4 (−25.2–43.0)0.611
SAA7.0 (5.3–9.2)26.0 (3.0–54.0)8.9 (5.1–15.4)0.2 (−37.8–61.3)0.102
IGF-1116.8 (106.8–127.7)0.8 (−4.7–6.6)123.0 (102.7–147.3)−0.3 (−12.8–14.1)0.791
IGF-BP13.1 (2.5–3.9)−4.9 (−18.4–10.8)3.1 (2.0–4.8)−2.0 (−31.8–40.7)0.781
IGF-BP3566.0 (519.3–616.8)−1.5 (−5.8–2.9)540.7 (456.9–639.9)−0.2 (−10.1–10.8)0.666
Insulin5.8 (4.8–7.1)−17.2 (−28.9 to −3.5)6.4 (4.3–9.6)−24.7 (−47.9–8.7)0.383
  • Abbreviation: CI, confidence interval.

  • aOne outlier removed.

  • *Geometric mean calculated from mixed-effects model with age, time since diagnosis, and antihormone therapy, NSAID, and statin use as covariates.